Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients

Aya Bassam; Abdulkadir Mohammed Noori Jassim; Olfat A. Nief

doi:10.12991/jrespharm.1797966

Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients

Abstract

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, which also makes up the highest percentage of mortality caused by cancer globally. HCC is linked to many risk factors as the liver is a central, vital organ that interacts with many of the body's processes. Oxidative stress is shown to be involved in the pathogenesis and progression of HCC. Paraoxonase (PON) is one of the antioxidant enzymes that participate in many biological reactions in different organs. The current study aimed to investigate the systemic role of PON in HCC patients and its correlation with liver tests. Accordingly, case-control study were conducted on 120 subjects divided into two groups: 60 control and 60 HCC patients of matching age. Serum level of PON was observed to be significantly lower in HCC patients compared to non-HCC individuals, correlating negatively with the activity of gamma-glutamyl transferase (GGT), where it was observed to be markedly elevated in HCC patients. Additionally, the activities of alanine aminotransferase, aspartate transaminase, and alkaline phosphatase were also significantly increased. PON has shown good predictive sensitivity (0.839) for HCC. In conclusion, reducing PON in HCC can play an important role in the progression of the disease and can be used successfully for the prognosis of liver cancer.

Keywords

References

[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917. https://doi.org/10.1002/ijc.25516.
[2] Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491. https://doi.org/10.1200/jco.2008.20.7753.
[3] Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. https://doi.org/10.2147/jhc.s61146.
[4] Tang F, Wang N. Identification and validation of ferroptosis-related prognostic risk model and immune landscape in hepatocellular carcinoma. Immunobiology. 2023;228(5):152723. https://doi.org/10.1016/j.imbio.2023.152723.
[5] Knapp J, Babu H, Benjamin S, Shapiro A. Hepatocellular carcinoma metastatic to the pituitary gland without an identifiable primary lesion. Rad Case Rep. 2024;19(4):1263-1267. https://doi.org/10.1016%2Fj.radcr.2023.12.030.
[6] Li W, Zhao B, Wang Q, Lu J, Wu X, Chen X. Integrated analysis of tumour-derived exosome-related immune genes to predict progression and immune status of hepatocellular carcinoma. Clin Immunol. 2023;256:109774. https://doi.org/10.1016/j.clim.2023.109774.
[7] Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. https://doi.org/10.1186/1479-5876-9-171.
[8] Sies H, Berndt C, Jones DP. Oxidative Stress. Annu Rev Biochem. 2017;86:715-748. https://doi.org/10.1146/annurev-biochem-061516-045037.

[9] Abod K, Mohammed M, Taay YM, editors. Evaluation of total oxidant status and antioxidant capacity in sera of acute-and chronic-renal failure patients. J Phys: Conf Ser. 2021: 1853(1):012038. http://dx.doi.org/10.1088/1742- 6596/1853/1/012038.
[10] Gulcin İ. Antioxidants and antioxidant methods: an updated overview. Arch Toxicol. 2020;94(3):651-715. https://doi.org/10.1007/s00204-020-02689-3.
[11] Taler-Verčič A, Goličnik M, Bavec A. The structure and function of paraoxonase-1 and its comparison to paraoxonase-2 and -3. Molecules . 2020;25(24):5980. https://doi.org/10.3390/molecules25245980.
[12] Kotur-Stevuljević J, Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, Miljković M, Sopić M, Munjas J, Mihajlović M, Spasić S, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Paraoxonase 1 and atherosclerosis-related diseases. Biofactors. 2020;46(2):193-205. https://doi.org/10.1002/biof.1549.
[13] Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Sala J, Masiá R, Marrugat J. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab. 2003;88(11):5422-5426. https://doi.org/10.1210/jc.2003-030648.
[14] Borovkova EI, Antipova NV, Komeenko TV, Shakhparonov MI, Borovkov IM. Paraoxonase: The universal factor of antioxidant defense in human body. Vestn Ross Akad Med Nauk. 2017;72(1):5-10. https://doi.org/10.15690/vramn764.
[15] Shokri Y, Variji A, Nosrati M, Khonakdar-Tarsi A, Kianmehr A, Kashi Z, Bahar A, Bagheri A, Mahrooz A. Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: Genotypic and phenotypic evaluation. Diabetes Res Clin Pract. 2020;161:108067. https://doi.org/10.1016/j.diabres.2020.108067.
[16] Watanabe J, Kotani K, Gugliucci A. Paraoxonase 1 and chronic obstructive pulmonary disease: A Meta-Analysis. Antioxidants (Basel). 2021;10(12):1891. https://doi.org/10.3390%2Fantiox10121891.
[17] Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, Levy E. The three-gene paraoxonase family: Physiologic roles, actions and regulation. Atherosclerosis. 2011;214(1):20-36. https://doi.org/10.1016/j.atherosclerosis.2010.08.076.
[18] Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact. 2010;187(1-3):355-361. https://doi.org/10.1016%2Fj.cbi.2010.03.033.
[19] Camps J, Marsillach J, Rull A, Alonso-Villaverde C, Joven J. Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv Exp Med Biol. 2010;660:5- 18. https://doi.org/10.1007/978-1-60761-350-3_2.
[20] Cao X, Cao Z, Shao Y, Liu C, Yan G, Meng X, Zhang L, Chen C, Huang G, Shu H, Lu H. Analysis of serum paraoxonase 1 using mass spectrometry and lectin ımmunoassay in patients with alpha-fetoprotein negative hepatocellular carcinoma. Front Oncol. 2021;11:651421. https://doi.org/10.3389%2Ffonc.2021.651421.
[21] Ding GY, Zhu XD, Ji Y, Shi GM, Shen YH, Zhou J, Fan J, Sun HC, Huang C. Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. Ann Transl Med. 2020;8(5):204. https://doi.org/10.21037%2Fatm.2020.01.44.
[22] Yu Z, Ou Q, Chen F, Bi J, Li W, Ma J, Wang R, Huang X. Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival. J Transl Med. 2018;16(1):327. https://doi.org/10.1186%2Fs12967-018-1707-0.
[23] Sun C, Chen P, Chen Q, Sun L, Kang X, Qin X, Liu Y. Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Acta Biochim Biophys Sin (Shanghai). 2012;44(9):765-773. https://doi.org/10.1093/abbs/gms055.
[24] Makhloof MR, Badran DI, Hassan MF, Hassan FM, Abdel Atty M-EA. Serum Paraoxonase-1 (PON1) activity and concentration: A new biomarker in Egyptian Patients with liver cirrhosis and hepatocellular carcinoma. Afro-Egypt J Infect Endem Dis. 2019;9(2):185-192. https://dx.doi.org/10.21608/aeji.2019.11213.1018.
[25] Medina-Díaz IM, Ponce-Ruíz N, Rojas-García AE, Zambrano-Zargoza JF, Bernal-Hernández YY, González-Arias CA, Barrón-Vivanco BS, Herrera-Moreno JF. The relationship between cancer and paraoxonase 1. Antioxidants (Basel). 2022;11(4):697.https://doi.org/10.3390/antiox11040697.
[26] Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J. Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002;48(2):261-268.
[27] Ferré N, Marsillach J, Camps J, Mackness B, Mackness M, Riu F, Coll B, Tous M, Joven J. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol. 2006;45(1):51-59. https://doi.org/10.1016/j.jhep.2005.12.018.
[28] Saeidi M, Shakeri R, Marjani A, Khajeniazi S. Alzheimer's disease and paraoxonase 1 (PON1) gene polymorphisms. Open Biochem J. 2017;11:47-55. https://doi.org/10.2174/1874091x01711010047.
[29] Ellidag HY, Eren E, Aydin O, Yıldırım M, Sezer C, Yilmaz N. Multiple myeloma: Relationship to antioxidant esterases. Med Princ Pract. 2014;23(1):18-23. https://doi.org/10.1159%2F000355826.
[30] Bhattacharyya GS, Babu KG, Malhotra H, Ranade AA, Murshed S, Datta D. Hepatocellular carcinoma in India. Chin Clin Oncol. 2013;2(4):41. https://doi.org/10.3978/j.issn.2304-3865.2013.09.05.
[31] Akinloye OA, Akinloye DI, Lawal MA, Shittu MT, Metibemu DS. Terpenoids from Azadirachta indica are potent inhibitors of Akt: Validation of the anticancer potentials in hepatocellular carcinoma in male Wistar rats. J Food Biochem. 2021;45(1):e13559. https://doi.org/10.1111/jfbc.13559.
[32] Hosseini-Khah Z, Babaei MR, Tehrani M, Cucchiarini M, Madry H, Ajami A, Rakhshani N, Rafiei A, Nikbin B. SOX2 and Bcl-2 as a novel prognostic value in hepatocellular carcinoma progression. Curr Oncol. 2021;28(4):3015- 3029. https://doi.org/10.3390/curroncol28040264.
[33] Taha H, Elfar N, Haffez H, Hassan ZA. Raptinal silver nanoparticles: new therapeutic advances in hepatocellular carcinoma mouse model. Naunyn Schm Arch Pharmacol. 2021;394(2):279-289. https://doi.org/10.1007/s00210-020- 01973-4.
[34] Elewa MAF, Eldehna WM, Hamdan AME, Abd El-Kawi SH, El-Kalaawy AM, Majrashi TA, Barghash RF, AbdelAziz HA, Hashem KS, Al-Gayyar MMH. WRH-2412 alleviates the progression of hepatocellular carcinoma through regulation of TGF-β/β-catenin/α-SMA pathway. J Enzyme Inhib Med Chem. 2023;38(1):2185761. https://doi.org/10.1080/14756366.2023.2185761.
[35] Al-Jumaily EF, Khaleel FM. The effect of chronic liver diseases on some biochemical parameters in patients serum. Curr Res J Biol Sci. 2012;4(5):638-642.
[36] Zakhary NI, El-Merzabani MM, El-Sawi NM, Saleh SM, Moneer MM, Mohamad RH. Impact of different biochemical markers in serum of patients with benign and malignant liver diseases. J Adv Res. 2011;2(1):49-55. http://dx.doi.org/10.1016/j.jare.2010.08.001.
[37] Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263-355. https://doi.org/10.1080/20014091084227.
[38] Fentiman IS. Gamma-glutamyl transferase: Risk and prognosis of cancer. Br J Cancer. 2012;106(9):1467-1468. https://doi.org/10.1038/bjc.2012.128.
[39] Carr BI, Akkiz H, Bag HG, Karaoğullarından U, Yalçın K, Ekin N, Özakyol A, Altıntaş E, Balaban HY, Şimşek H, Uyanıkoğlu A, Balkan A, Kuran S, Üsküdar O, Ülger Y, Güney B, Delik A. Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis. J Transl Sci. 2021;7(3):10.15761/jts.1000446. https://doi.org/10.15761/jts.1000446.
[40] Hanigan MH, Pitot HC. Gamma-glutamyl transpeptidase--its role in hepatocarcinogenesis. Carcinogenesis. 1985;6(2):165-172. https://doi.org/10.1093/carcin/6.2.165.
[41] Fu S, Guo Z, Li S, Kuang M, Hu W, Hua Y, He X, Peng B. Prognostic value of preoperative serum gammaglutamyltranspeptidase in patients with hepatocellular carcinoma after hepatectomy. Tumour Biol. 2016;37(3):3433- 3440. https://doi.org/10.1007/s13277-015-4136-1.
[42] Akkiz H, Carr BI, Yalçın K K, Guerra V, Kuran S, Altıntaş E, Üsküdar O, Karaoğullarından Ü, Özakyol A, Tokmak S, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Yalçın Polat K, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Ballı T, Demir A, Arslan B, Doran F. Characteristics of hepatocellular carcinoma aggressiveness factors in Turkish patients. Oncology. 2018;94(2):116-124. https://doi.org/10.1159%2F000484564.
[43] Zhang CH, Ni XC, Chen BY, Qiu SJ, Zhu YM, Luo M. Combined preoperative albumin-bilirubin (ALBI) and serum γ-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection. J Cancer. 2019;10(20):4836-4845. https://doi.org/10.7150/jca.33877.
[44] Wang L, Li Q, Zhang J, Lu J. A novel prognostic scoring model based on albumin and γ-glutamyltransferase for hepatocellular carcinoma prognosis. Cancer Manag Res. 2019;11:10685-10694. https://doi.org/10.2147%2FCMAR.S232073.
[45] Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer. 2019;19(1):841. https://doi.org/10.1186/s12885-019-6011-8.
[46] Bai C, Zhang M, Zhang Y, He Y, Dou H, Wang Z, Wang Z, Li Z, Zhang L. Gamma-glutamyltransferase activity (GGT) Is a long-sought biomarker of redox status in blood circulation: A retrospective clinical study of 44 types of human diseases. Oxid Med Cell Longev. 2022;2022:8494076. https://doi.org/10.1155%2F2022%2F8494076.
[47] El Sebaii H, Abd El-Hamid A, Abou Elnour E, El-Azab G, El-Helbawy N, El-Naidany S. mRNA expression of interleukin-17 in viral hepatitis B and hepatocellular carcinoma patients. Menoufia Med J. 2018;31(3):753-761.
[48] Li J, Li Z, Hao S, Wang J, Chen W, Dai S, Hou Z, Chen B, Zhang Y, Liu D. Inversed albumin-to-globulin ratio and underlying liver disease severity as a prognostic factor for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Diagn Interv Rad. 2023;29(3):520- 528. https://doi.org/10.5152%2Fdir.2022.211166.
[49] Abdelmoez FA-b, Imam HM, Idriss NK, Wahid LA, Abbas WA, Abozaid MAA, Abdelwahab HM. The role of Hepatitis C virus and possible risk factors in development of hepatocellular carcinoma: 400 Patients based study. Egypt J Intern Med. 2019;31(1):64-72. https://doi.org/10.4103/ejim.ejim_50_18.
[50] Baghdady I, Fouad F, Sayed M, Shoaib A, Salah Y, Elshayeb E. Serum markers for the early detection of hepatocellular carcinoma in patients with chronic viral hepatitis C infection. Menoufia Med J. 2014;27(3):544-550.
[51] Mohamed BF, Serag WM, Abdelal RM, Elsergany HF. S100A14 protein as diagnostic and prognostic marker in hepatocellular carcinoma. Egypt Liver J. 2019;9(1):9. http://dx.doi.org/10.1186/s43066-019-0015-6.
[52] Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103(9):1856-1864. https://doi.org/10.1002/cncr.20976.
[53] Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR Jr, Lee DH. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med. 2004;37(7):1018-1023. https://doi.org/10.1016/j.freeradbiomed.2004.06.032.
[54] Manna MJ, Jabur MS, Mohammad HR, Abdulamir HA. The potential effect of topical aminophylline on acute glaucoma model. Res J Pharm Technol. 2022; 15(1):197-200. http://dx.doi.org/10.52711/0974-360X.2022.00032.
[55] Al-Shammari AH, Khudhur AQ, Abdulamir HA. Effect of intralesional levofloxacin in the treatment of cutaneous leishmaniasis. J Popul Ther Clin Pharmacol. 2023;30(1):e92–e100. http://dx.doi.org/10.47750/jptcp.2023.1028.
[56] Aldafaay AAA, Abdulamir HA, Abdulhussain HA, Badry AS, Abdulsada AK. The use of urinary α-amylase level in a diagnosis of chronic renal failure. Res J Pharm Technol. 2021; 14(3):1597-1600. http://dx.doi.org/10.5958/0974- 360X.2021.00283.3.

Details

Primary Language

English

Subjects

Pharmaceutical Chemistry

Journal Section

Research Article

Authors

Aya Bassam ^*
0009-0001-8948-2952
Iraq

Abdulkadir Mohammed Noori Jassim
0000-0002-9179-2466
Iraq

Olfat A. Nief This is me
0000-0002-7806-064X
Iraq

Publication Date

November 2, 2025

Submission Date

April 25, 2024

Acceptance Date

May 23, 2024

Published in Issue

Year 2025 Volume: 29 Number: 6

DOI

https://doi.org/10.12991/jrespharm.1797966

IZ

https://izlik.org/JA98SC66UU

Cite

RIS / Bibtex

APA

Bassam, A., Mohammed Noori Jassim, A., & Nief, O. A. (2025). Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients. Journal of Research in Pharmacy, 29(6), 2395-2401. https://doi.org/10.12991/jrespharm.1797966

AMA

1.Bassam A, Mohammed Noori Jassim A, Nief OA. Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients. J. Res. Pharm. 2025;29(6):2395-2401. doi:10.12991/jrespharm.1797966

Chicago

Bassam, Aya, Abdulkadir Mohammed Noori Jassim, and Olfat A. Nief. 2025. “Evaluation of Serum Paraoxonase and Its Association With Hepatocellular Carcinoma in Iraqi Patients”. Journal of Research in Pharmacy 29 (6): 2395-2401. https://doi.org/10.12991/jrespharm.1797966.

EndNote

Bassam A, Mohammed Noori Jassim A, Nief OA (November 1, 2025) Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients. Journal of Research in Pharmacy 29 6 2395–2401.

IEEE

[1]A. Bassam, A. Mohammed Noori Jassim, and O. A. Nief, “Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients”, J. Res. Pharm., vol. 29, no. 6, pp. 2395–2401, Nov. 2025, doi: 10.12991/jrespharm.1797966.

ISNAD

Bassam, Aya - Mohammed Noori Jassim, Abdulkadir - Nief, Olfat A. “Evaluation of Serum Paraoxonase and Its Association With Hepatocellular Carcinoma in Iraqi Patients”. Journal of Research in Pharmacy 29/6 (November 1, 2025): 2395-2401. https://doi.org/10.12991/jrespharm.1797966.

JAMA

1.Bassam A, Mohammed Noori Jassim A, Nief OA. Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients. J. Res. Pharm. 2025;29:2395–2401.

MLA

Bassam, Aya, et al. “Evaluation of Serum Paraoxonase and Its Association With Hepatocellular Carcinoma in Iraqi Patients”. Journal of Research in Pharmacy, vol. 29, no. 6, Nov. 2025, pp. 2395-01, doi:10.12991/jrespharm.1797966.

Vancouver

1.Aya Bassam, Abdulkadir Mohammed Noori Jassim, Olfat A. Nief. Evaluation of serum paraoxonase and its association with hepatocellular carcinoma in Iraqi patients. J. Res. Pharm. 2025 Nov. 1;29(6):2395-401. doi:10.12991/jrespharm.1797966